Minerva Neurosciences, Inc. — Form 8-K
Filed November 16, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 28/100
What the filing says
Minerva Neurosciences held an investor conference detailing its roluperidone program for schizophrenia negative symptoms. The company presented data from C03 (244 patients) and C07 (515 patients) Phase 2b/3 trials showing statistically significant improvements in negative symptom scores (NSFS, p≤0.043) and functioning (PSP, p≤0.016) versus placebo at 64 mg monotherapy, with low relapse rates. The ongoing C19 confirmatory Phase 3 trial (~380 patients across ~40 US and European sites) is actively enrolling with a 12-week primary efficacy endpoint and 52-week safety/relapse assessment; company expects Phase A (12-week) data in second half of 2027. FDA alignment was reached on the monotherapy study design in September 2024. The company secured $200M financing in October 2025 (led by Vivo Capital) to fund C19, NDA resubmission, and commercialization prep. Market opportunity estimated at ~900k stable US patients and >$2B peak annual sales potential.
Why this rating
Early-stage biotech ($7M market cap) with Phase 3 trial underway for first potential negative-symptoms therapy; near-term data catalyst, but approval uncertain and commercial viability unproven. Event is routine disclosure of trial progress.
See more from November 16, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.